Drug Profile


Alternative Names: Carteolol hydrochloride/latanoprost; Mikeluna; OPC-1085EL

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Glaucoma; Ocular hypertension

Most Recent Events

  • 29 Sep 2016 Registered for Glaucoma in Japan (Ophthalmic)
  • 29 Sep 2016 Registered for Ocular hypertension in Japan (Ophthalmic)
  • 28 Sep 2016 Otsuka Pharmaceutical and Senju Pharmaceutical sign an agreement, to co-promote the combined carteolol/latanoprost and other ophthalmic treatments in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top